On-demand webinar: Visualize immune cells abundance in tumors to determine therapeutic efficacy

The significance of spatial immune signatures lies in the determination of immune cell types, activation status, spatial distribution, and intricate interactions within tissues. These unique signatures play a pivotal role in various fields, particularly cancer, immunology, and autoimmune diseases, where the effectiveness of treatments is intricately linked to the immune response within tissues. By incorporating spatial immune signatures into phase II trials, early insights into treatment responses can be gained, offering a reflection of clinical outcomes. This approach expedites decision-making regarding drug candidate progression in later phases of clinical development, ultimately saving valuable time and resources for your program.

Watch this on-demand presentation led by industry expert Corinne Ramos, Director of R&D, Aliri Bioanalysis, as we unveil our clinical trial findings alongside the innovative technologies and state-of-the-art computational tools that have revolutionized our capacity to observe and decipher spatial immune signatures.

What you’ll learn:

  • Understand the significance of spatial immune signatures in assessing early treatment efficacy.
  • Explore our patient-centric approach, which includes baseline profiling and ongoing monitoring.
  • Gain insights into leveraging these techniques for drug development.
  • Discover how this approach can save your program valuable time and resources.

Watch on-demand now

Multimodal stratification of predictive biomarker in lung cancer: A focus on immune checkpoint inhibitor


Dive into the complex landscape of immune checkpoint inhibitors (ICIs) in lung cancer in our poster presentation. 
As the use of immunotherapy in early-stage non-small cell lung cancer (NSCLC) remains a challenge, we offer a spatially-informed approach to identify useful biomarkers. By using spatial biomarker assays, and analysis involving spatial transcriptomics and proteomics, we reveal the cell-to-cell interactions in the tumor microenvironment.  
Download our poster to explore our findings and gain insights into the suitability of ICIs for personalized therapy

Download Now

Spatial distribution of B cells and lymphocyte clusters for the treatment of non-small cell lung cancer


Explore the spatial organization of tertiary lymphoid structures (TLS) in non-small cell lung cancer (NSCLC) and its impact on ant-PD-1 treatment response in our poster presentation.  
Using high-plex imaging mass cytometry staining, we investigated the relationship between TLS spatial organization, the tumor microenvironment, and patient response to therapy. We leveraged deep learning for cell segmentation and characterization to identify that the presence of tumor-associated TLS correlates with a positive response to ant-PD-1 therapy.  
Download our poster to dive into this spatial distribution insight and its potential impact on immunotherapies.

Download Now

Highly sensitive analysis using EVOSEP-LC-MS/MS assay for targeted PD-L1 and PD-1 expression level for predicting response to immune checkpoint inhibitors


Explore our recent poster presentation, which dives into a highly sensitive analysis using an EVOSEP-LC-MS/MS assay, with a focus on targeted PD-L1 and PD-1 expression levels to predict responses to immune checkpoint inhibitors (ICIs). 
We address the limitations of traditional PD-L1 and PD-1 immunoassays and their uncertain clinical value across tumor types. Through analysis of our robust method against routine immunoassays, and use of Overall Response Rate (ORR), we offer a new perspective on the predictive power of biomarkers for non-small cell lung cancer (NSCLC) therapy.  
Download our poster to discover the potential of this innovative approach.  

Download Now

Exploring Protein Analysis: Techniques and Applications in Bioanalysis

The foundation of bioanalytical research lies in the analysis of proteins, offering intricate insights of life at the molecular level. By deconstructing the aspects of protein structures, functions, and expressions, we unlock invaluable insights of disease mechanisms, drug responses, and cellular processes.  

Aliri’s expertise in mass spectrometry generates precise data, guiding us toward pivotal discoveries in diagnostics, therapies, and individualized treatments. View our on-demand webinar where industry experts Shane Karnik, Senior Laboratory Director, Edward Brewer, Senior Director of R&D, and Matthew Hartle, Analytical Chemist, cover:  

  • The current state of the industry and how Aliri is adapting digital tools to explore proteins. 
  • Various approaches to streamline workflows related to protein analysis. 
  • Methodologies that aid in differentiating protein species. 
  • Guidance for Regulatory GLP and human-clinical support. 
  • Future trends and emerging techniques in the protein analysis space.

Watch on-demand now

A bioanalytical discovery strategy for fast and flexible decision making

When navigating drug discovery, it is critical to strategically balance project timelines and investments, and to select a reliable bioanalysis partner who is fully dedicated to the success of your program. Our ability to provide technical expertise and quick turnarounds will enable you to select your drug candidate and move on to the next phase of your project with ease and efficiency.

View our on-demand webinar where industry experts Edward Brewer, Senior Director of R&D, Mass Spectrometry and Systems Validation, and Ryan Adler, Manager of Laboratory Operations, cover: 

  • Advancements in Bioanalysis and strategic techniques used to quantify drug compounds during the discovery process.  
  • How our streamlined workflows enable fast and flexible decision-making and keep lead times down to 6-8 weeks.   
  • Navigating challenges faced during the discovery phase and exploring strategies to overcome these potential obstacles.   
  • How we advance molecules with ease and precision from Discovery to GLP.

Watch on-demand now

LC/MS/MS VS. LC/HRMS: Identifying and quantifying oligonucleotides 


LC/MS/MS and LC/HRMS are formidable instruments employed in mass spectrometry for the identification and quantification of Oligonucleotides (OGNTs). Utilizing these approaches, drug developers can obtain detailed insights into the composition and structure of molecules for biotechnology and pharmaceuticals.

Considerations for choosing the right approach for your drug development project will depend on: 

  • What instrument you have 
  • Where you want to go 
  • How much information you want to collect in a single injection 

Discover which technique is best for you.

Download Now

Optimizing small molecule drug development strategies: A step by step approach to a rugged method

Creating a rugged method for the development of small molecule drugs is crucial in the quest for successful therapies. A systematic approach not only guarantees data consistency and reliability but also empowers you to make well-informed decisions, ultimately boosting project efficiency and success.

To help you navigate the complexities and uncertainties that come with advancing small molecules for drug development, we’ve outlined a robust strategy that includes 7 crucial steps.

Download our fact sheet to learn more.

Download Now

Oligonucleotides: A Bioanalytical CRO’s Perspective on Current and Future State

Since the first oligonucleotide (OGNT) drug was approved by the FDA for clinical use in 1998, the industry has made significant progress in the advancement of techniques, technology, and development methods. However, due to the complexity and sensitivity of OGNTs, there are still challenges to navigate and overcome within drug development and bioanalytical analysis.

Join oligonucleotide bioanalysis SME Troy Voelker, Director of Laboratory Operations at Aliri, as he discusses:

  • Current and future state of the bioanalysis of OGNTs
  • Common approaches to bioanalysis of OGNTs
  • Evaluating and selecting the optimal and strategic approach

View Webinar

A Comprehensive Guide to Optimizing Your Small Molecule Drug Development Strategy 

Given that small molecules make up more than 50% of the drug development pipeline, adopting a proactive non-clinical to clinical strategy is crucial for accelerating your program.

A holistic bioanalysis strategy that incorporates spatial analysis allows researchers to produce quality data, identify drug targets, evaluate efficacy, and optimize delivery. Join industry experts Troy Voelker and Corinne Ramos as they cover a step-by-step approach to a rugged method, including:

  • Strategies moving from pre-clinical to clinical
  • Spatial bioanalysis and moving into GLP
  • Molecule stability and reproducibility
  • Handling matrices and compounds
  • Different instrumentation and uses
  • Cold storage check list
  • Ongoing use of ICH M-10

View our on-demand webinar to learn how to implement a comprehensive strategy that expedites the development of your small molecule.

View Webinar